CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Victoria Long Weekend Closure - Richardson Laboratory will be closed on May 20 (Queen’s Holiday) and May 23 (Victoria Day)
Shipment of Specimens for Banking + Kit Supply
“Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)” (NCT04918186), is sponsored by CRI clinical partner the Canadian Cancer Trials Group (CCTG), and is open and actively recruiting patients to sites in Canada and, in the second half of 2022, will open sites in
CLC3E sub-study titled: An Economic Analysis of Early VS Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Companion Analysis to CCTG CLC.3 / SWOG 1925 Randomized
CCTG congratulates the Hotel-Dieu du Quebec MA39 trial team for their CCTG Phase III Team Award presented at the CCTG 2022 Spring Meeting.
The award is given to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance. The team includes, Alexandre Villeneuve-Gauthier, Josee Allard, Dr. Valerie Theberge, Sophie Pouliot, Isabelle Desrosiers.
Dr. Aly-Khan A. Lalani, B.Sc (Hons), MD, FRCPC, has been awarded the 2022 CCTG Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award recognizing his work as a new investigator who has contributed significantly to the conduct of an IND trials.
The Allan Blair Cancer Centre IND234 trial team has been awarded the 2022 CCTG IND Team Award for performance in trial accrual, local activation timelines, and compliance metrics, team performance.
Dr. Jonathan Loree has been recognized for his Phase III research contributions with the CCTG 2022 Dr. Ralph Meyer Phase III Young Investigator Award.
